Board of Directors
Michael Graves
Chairman of the Board, Executive Committee Chair, Nominating and Corporate Governance Committee Chair, Compensation Committee Chair
Mike has served as a member of Eagle’s board of directors since 2013. Mike is Chairman of the board of directors of Nanocopoeia, Inc., and a member of the board of directors of RiboCor, Inc. Mike has a wide variety of pharmaceutical industry experience including his position as CEO and President of
Scott Tarriff
Founder, President and Chief Executive Officer, Director
Scott Tarriff is the founder of Eagle Pharmaceuticals and has served as its Chief Executive Officer and as a member of the Board since its inception in January 2007. Mr. Tarriff has also served as Eagle’s President since September 2021. Prior to founding Eagle, Mr.
Luciana Borio MD
Board Member
Dr. Borio has served as Senior Vice President of In-Q-Tel, an independent strategic investment firm that supports the mission of the United States national security community, since 2019, and served as a member of President Biden’s Transition COVID-19 Advisory Board from November 2020 to January
Richard A. Edlin, J.D.
Board Member, Compensation Committee, Nominating and Corporate Governance Committee
Rich is currently the Vice Chair, Chair of Litigation Practice in New York and the Business & Regulatory Financial Services Litigation Group, and a member of the Executive Committee of the law firm Greenberg Traurig, LLP. Rich is a member of the Board of Trustees of the Urban Justice Center; a
Robert L. Glenning
Board Member, Audit Committee, Nominating and Corporate Governance Committee
Bob has over 30 years of experience in the healthcare industry and currently serves as President of the Financial Services and Information Technology Divisions and CFO at Hackensack Meridian Health, the most comprehensive healthcare delivery network in the state of New Jersey.
Steven Ratoff
Board Member, Audit Committee Chair, Compensation Committee
Steve has served as a member of our board of directors since Eagle’s inception in 2007. From 2010, he has served as President and Chief Executive Officer of NovaDel Pharma, Inc., filling a number of executive positions since joining their board of directors in 2005, and is currently serving as its
Jennifer Simpson, PhD
Board Member, Nominating and Corporate Governance Committee
Dr. Simpson is the President and CEO of Panbela Therapeutics as of July 2020. She previously served as President and CEO of Delcath, 2015-2020. Prior to Delcath, Dr. Simpson served in positions of increasing responsibility at ImClone Systems (a subsidiary of Eli Lilly and Company), most recently as